News

Read about the progress of individual NINDS PDBP projects and learn about presentations and workshops that are relevant to the PDBP.
Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson's disease.

  • Sankowski B
  • Księżarczyk K
  • Raćkowska E
  • Szlufik S
  • Koziorowski D
  • Giebułtowicz J
Cholinergic denervation in idiopathic rapid eye movement sleep behaviour disorder patients.

  • Gersel Stokholm M
  • Iranzo A
  • Østergaard K
  • Serradell M
  • Otto M
  • Bacher Svendsen K
  • Garrido A
  • Vilas D
  • Fedorova TD
  • Santamaria J
  • Møller A
  • Gaig C
  • Hiraoka K
  • Brooks DJ
  • Okamura N
  • Borghammer P
  • Tolosa E
  • Pavese N
Neurotoxic and Neuroprotective Role of Exosomes in Parkinson's Disease.

  • Longoni B
  • Fasciani I
  • Kolachalam S
  • Pietrantoni I
  • Marampon F
  • Petragnano F
  • Aloisi G
  • Coppolino MF
  • Rossi M
  • Scarselli M
  • Maggio R
Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALS.

  • Zhu S
  • Wuolikainen A
  • Wu J
  • Öhman A
  • Wingsle G
  • Moritz T
  • Andersen PM
  • Forsgren L
  • Trupp M
Serotonin release measured in the human brain: a PET study with [<sup>11</sup>C]CIMBI-36 and d-amphetamine challenge.

  • Erritzoe D
  • Ashok AH
  • Searle GE
  • Colasanti A
  • Turton S
  • Lewis Y
  • Huiban M
  • Moz S
  • Passchier J
  • Saleem A
  • Beaver J
  • Lingford-Hughes A
  • Nutt DJ
  • Howes OD
  • Gunn RN
  • Knudsen GM
  • Rabiner EA
VGF peptides as novel biomarkers in Parkinson's disease.

  • Cocco C
  • Corda G
  • Lisci C
  • Noli B
  • Carta M
  • Brancia C
  • Manca E
  • Masala C
  • Marrosu F
  • Solla P
  • Manconi B
  • Bongioanni P
  • Ferri GL
Assessing the role of nocturnal core body temperature dysregulation as a biomarker of neurodegeneration.

  • Raupach AK
  • Ehgoetz Martens KA
  • Memarian N
  • Zhong G
  • Matar E
  • Halliday GM
  • Grunstein R
  • Lewis SJG
Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.

  • Huebecker M
  • Moloney EB
  • van der Spoel AC
  • Priestman DA
  • Isacson O
  • Hallett PJ
  • Platt FM
Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions.

  • Yamada M
  • Komatsu J
  • Nakamura K
  • Sakai K
  • Samuraki-Yokohama M
  • Nakajima K
  • Yoshita M
Blood biomarkers with Parkinson's disease clusters and prognosis: the oxford discovery cohort.

  • Lawton M
  • Baig F
  • Toulson G
  • Morovat A
  • Evetts SG
  • Ben-Shlomo Y
  • Hu MT
Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases.

  • Barbagallo C
  • Mostile G
  • Baglieri G
  • Giunta F
  • Luca A
  • Raciti L
  • Zappia M
  • Purrello M
  • Ragusa M
  • Nicoletti A

Press releases, workshop summaries, and editorials

Accelerating Research for Parkinson’s Disease

The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.

AMP PD

 

NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease

“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”